Pneumovax 23™

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Prophylaxis Invasive Pneumococcal Diseases and PneumoniaStreptococcus Pneumoniae Vaccines

Phase 2

Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population.

CompletedNCT00307008

GlaxoSmithKlineStreptococcus Pneumoniae Vaccines

Start: 2003-10-31End: 2005-02-28Updated: 2013-04-15

Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Population

CompletedNCT00307528

GlaxoSmithKlineProphylaxis Invasive Pneumococcal Diseases and Pneumonia

Start: 2004-01-20End: 2005-03-30Updated: 2019-10-30

Related Papers

Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: Randomised, controlled trials

Vaccine2013-10-2960 citations